Trials / Terminated
TerminatedNCT04254549
Rifaximin in Patients With Diabetic Gastroparesis
Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifaximin | 550 mg by mouth three times daily for 14 days |
| DRUG | Placebo | By mouth three times daily for 14 days |
Timeline
- Start date
- 2019-06-14
- Primary completion
- 2025-04-08
- Completion
- 2025-04-11
- First posted
- 2020-02-05
- Last updated
- 2025-11-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04254549. Inclusion in this directory is not an endorsement.